BR112016006388A2 - inibidor seletivo da fosfatidilinositol 3-quinase gama - Google Patents

inibidor seletivo da fosfatidilinositol 3-quinase gama

Info

Publication number: BR112016006388A2
Authority: BR; Brazil
Prior art keywords: gamma inhibitor; kinase gamma; selective; selective phosphatidylinositol; phosphatidylinositol
Prior art date: 2013-09-25

Application number

BR112016006388A

Other languages

English (en)

Portuguese (pt)

Inventor

Aronov Alex

O'dowd Hardwin

Green Jeremy

John Boyd Michael

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-09-25

Filing date

2014-09-25

Publication date

2017-08-01

2014-09-25 Application filed by Vertex Pharma filed Critical Vertex Pharma

2017-08-01 Publication of BR112016006388A2 publication Critical patent/BR112016006388A2/pt

Links

239000003112 inhibitor Substances 0.000 title abstract 2
108091007960 PI3Ks Proteins 0.000 title 1
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 title 1
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

BR112016006388A 2013-09-25 2014-09-25 inibidor seletivo da fosfatidilinositol 3-quinase gama BR112016006388A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361882473P	2013-09-25	2013-09-25
PCT/US2014/057499 WO2015048318A1 (fr)	2013-09-25	2014-09-25	Inhibiteur sélectif de la phosphatidylinositol-3-kinase-gamma

Publications (1)

Publication Number	Publication Date
BR112016006388A2 true BR112016006388A2 (pt)	2017-08-01

Family

ID=51795739

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR112016006388A BR112016006388A2 (pt)	2013-09-25	2014-09-25	inibidor seletivo da fosfatidilinositol 3-quinase gama

Country Status (18)

Country	Link
US (1)	US10301304B2 (fr)
EP (2)	EP3412668B1 (fr)
JP (1)	JP6340416B2 (fr)
KR (1)	KR20160058950A (fr)
CN (1)	CN105722838B (fr)
AU (1)	AU2014324873B2 (fr)
BR (1)	BR112016006388A2 (fr)
CA (1)	CA2925601C (fr)
CL (1)	CL2016000695A1 (fr)
ES (2)	ES2785053T3 (fr)
HK (1)	HK1223620A1 (fr)
IL (1)	IL244742A0 (fr)
MX (1)	MX2016003823A (fr)
RU (2)	RU2018142605A (fr)
SG (2)	SG11201602265PA (fr)
UA (1)	UA117032C2 (fr)
WO (1)	WO2015048318A1 (fr)
ZA (1)	ZA201702252B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
BR112016007467B1 (pt)	2013-10-04	2022-09-20	Infinity Pharmaceuticals, Inc	Compostos heterocíclicos e usos dos mesmos
WO2015051241A1 (fr)	2013-10-04	2015-04-09	Infinity Pharmaceuticals, Inc.	Composés hétérocycliques et leurs utilisations
CN106456628A (zh)	2014-03-19	2017-02-22	无限药品股份有限公司	用于治疗PI3K‑γ介导的障碍的杂环化合物
WO2016054491A1 (fr)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Composés hétérocycliques et leurs utilisations
JP6786529B2 (ja) *	2015-06-29	2020-11-18	バイオメッドバレーディスカバリーズ，インコーポレイティド	Ｌｐｔ−７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法
MX2018003058A (es)	2015-09-14	2018-08-01	Infinity Pharmaceuticals Inc	Formas solidas de derivados de isoquinolinona, proceso de fabricacion, composiciones que las contienen y metodos de uso de las mismas.
WO2017153527A1 (fr) *	2016-03-10	2017-09-14	Astrazeneca Ab	Nouveaux inhibiteurs de la phosphatidylinositol 3-kinase gamma
US10759806B2 (en)	2016-03-17	2020-09-01	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (fr)	2016-06-08	2017-12-14	Infinity Pharmaceuticals, Inc.	Composés hétérocycliques et leurs utilisations
WO2020210379A1 (fr)	2019-04-10	2020-10-15	Hangzhou Zhengxiang Pharmaceuticals Co., Ltd.	Inhibiteur de la phosphatidylinositol 3-kinase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR071717A1 (es) *	2008-05-13	2010-07-07	Array Biopharma Inc	Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
UY32582A (es) *	2009-04-28	2010-11-30	Amgen Inc	Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
JP5721187B2 (ja) *	2009-12-22	2015-05-20	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	ホスファチジルイノシトール３−キナーゼのイソインドリノンインヒビター

2014
- 2014-09-25 EP EP18180366.9A patent/EP3412668B1/fr active Active
- 2014-09-25 RU RU2018142605A patent/RU2018142605A/ru unknown
- 2014-09-25 UA UAA201604461A patent/UA117032C2/uk unknown
- 2014-09-25 KR KR1020167010907A patent/KR20160058950A/ko not_active Application Discontinuation
- 2014-09-25 CN CN201480060785.XA patent/CN105722838B/zh not_active Expired - Fee Related
- 2014-09-25 CA CA2925601A patent/CA2925601C/fr active Active
- 2014-09-25 RU RU2016115726A patent/RU2675814C2/ru not_active IP Right Cessation
- 2014-09-25 SG SG11201602265PA patent/SG11201602265PA/en unknown
- 2014-09-25 US US15/024,698 patent/US10301304B2/en active Active
- 2014-09-25 AU AU2014324873A patent/AU2014324873B2/en not_active Ceased
- 2014-09-25 ES ES18180366T patent/ES2785053T3/es active Active
- 2014-09-25 ES ES14789651.8T patent/ES2687593T3/es active Active
- 2014-09-25 BR BR112016006388A patent/BR112016006388A2/pt not_active Application Discontinuation
- 2014-09-25 SG SG10201802061TA patent/SG10201802061TA/en unknown
- 2014-09-25 MX MX2016003823A patent/MX2016003823A/es unknown
- 2014-09-25 JP JP2016516904A patent/JP6340416B2/ja not_active Expired - Fee Related
- 2014-09-25 EP EP14789651.8A patent/EP3049415B1/fr active Active
- 2014-09-25 WO PCT/US2014/057499 patent/WO2015048318A1/fr active Application Filing
2016
- 2016-03-23 IL IL244742A patent/IL244742A0/en unknown
- 2016-03-24 CL CL2016000695A patent/CL2016000695A1/es unknown
- 2016-10-17 HK HK16111963.2A patent/HK1223620A1/zh not_active IP Right Cessation
2017
- 2017-03-30 ZA ZA2017/02252A patent/ZA201702252B/en unknown

Also Published As

Publication number	Publication date
CL2016000695A1 (es)	2017-06-09
EP3412668A2 (fr)	2018-12-12
ES2687593T3 (es)	2018-10-26
SG11201602265PA (en)	2016-04-28
HK1223620A1 (zh)	2017-08-04
CN105722838B (zh)	2017-10-24
EP3049415B1 (fr)	2018-07-04
UA117032C2 (uk)	2018-06-11
EP3412668B1 (fr)	2020-02-05
JP2016531861A (ja)	2016-10-13
CN105722838A (zh)	2016-06-29
RU2675814C2 (ru)	2018-12-25
RU2018142605A (ru)	2019-02-04
CA2925601C (fr)	2022-11-01
ZA201702252B (en)	2019-06-26
CA2925601A1 (fr)	2015-04-02
MX2016003823A (es)	2016-08-01
AU2014324873B2 (en)	2018-11-08
IL244742A0 (en)	2016-04-21
EP3049415A1 (fr)	2016-08-03
US10301304B2 (en)	2019-05-28
EP3412668A3 (fr)	2018-12-19
SG10201802061TA (en)	2018-05-30
WO2015048318A1 (fr)	2015-04-02
US20160214980A1 (en)	2016-07-28
KR20160058950A (ko)	2016-05-25
RU2016115726A3 (fr)	2018-06-20
ES2785053T3 (es)	2020-10-05
JP6340416B2 (ja)	2018-06-06
AU2014324873A1 (en)	2016-04-21
RU2016115726A (ru)	2017-10-30

Legal Events

Date	Code	Title
2018-01-23	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2019-12-03	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2019-12-17	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2020-06-23	B11B	Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements

Publication	Publication Date	Title
BR112016006388A2 (pt)	2017-08-01	inibidor seletivo da fosfatidilinositol 3-quinase gama
CO2017011851A2 (es)	2018-02-09	Compuestos novedosos
BR112015021888A8 (pt)	2019-11-26	inibidores de dna-pk, seus usos e composição farmacêutica
NI201600071A (es)	2016-09-21	Compuestos de inhibidor de autotaxina
NI201400089A (es)	2015-04-13	COMPUESTOS DE OXAZOLIDIN - 2 - ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks
BR112015020389A2 (pt)	2017-07-18	compostos carbazol úteis como inibidores de bromodomínio
BR112014026703A2 (pt)	2017-06-27	inibidores de dna-pk
BR112017008659A2 (pt)	2018-01-30	?métodos e compostos de agonista de gip?
BR112016028845A2 (pt)	2017-08-22	composto, composição farmacêutica e uso de um composto
BR112015026023A2 (pt)	2017-07-25	derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
BR112016025470A2 (pt)	2017-08-15	?hdl terapêutico?
MY181602A (en)	2020-12-29	Isochromene derivatives as phosphoinositide 3-kinases inhibitors
BR112017003433A2 (pt)	2017-11-28	inibidores espirocíclicos de catepsina c
UY35276A (es)	2014-08-29	Nuevos compuestos que inhiben la actividad de Lp-PLA2
BR112017012504A2 (pt)	2018-01-09	derivados de piperidina como inibidores de hdac1/2
FI20115135A0 (fi)	2011-02-11	Mikrofibrilloidun selluloosan tulehduksia estävä vaikutus
UY35747A (es)	2015-04-30	Derivados sustituidos de fenilalanina
CR20150248A (es)	2015-07-01	Derivados de oxazolidin-2-ona-pirimidina
BR112017022158A2 (pt)	2018-07-03	compostos, composições farmacêuticas e uso de um composto
NI201600070A (es)	2016-09-21	Inhibidores tetracíclicos de autotaxina
BR112018011525A2 (pt)	2018-11-21	inibidores da tirosina quinase de bruton e métodos de seu uso
GT201700220A (es)	2018-12-19	Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap)
UY35745A (es)	2015-04-30	Derivados sustituidos de fenilalanina
BR112015013783A2 (pt)	2017-07-11	quitina ou seus derivados para a prevenção e / ou tratamento de parasitoses
PE20151669A1 (es)	2015-11-12	Compuestos de azetidiniloxifenilpirrolidina